Kronos Bio (KRON) Stock Price, News & Analysis

Company Overview

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Key Stats

• Today's Range: $0.88 to $0.90
• 50-Day Range: $0.67 to $0.91
• 52-Week Range: $0.65 to $1.60
• Volume: 347,765 shs
• Average Volume: 345,642 shs
• Market Capitalization: $54.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.63
• Consensus Rating: Hold

Kronos Bio Stock Analysis - MarketRank™

Kronos Bio scored higher than 66% of companies evaluated by MarketBeat, and ranked 383rd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Kronos Bio has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Kronos Bio has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Kronos Bio are expected to grow in the coming year, from ($1.36) to ($1.26) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kronos Bio is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kronos Bio is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kronos Bio has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.91% of the float of Kronos Bio has been sold short.

Short Interest Ratio / Days to Cover

Kronos Bio has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kronos Bio has recently increased by 37.67%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kronos Bio does not currently pay a dividend.

Dividend Growth

Kronos Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.91% of the float of Kronos Bio has been sold short.

Short Interest Ratio / Days to Cover

Kronos Bio has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kronos Bio has recently increased by 37.67%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.91

News Sentiment

Kronos Bio has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Kronos Bio this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for KRON on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Kronos Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,609.00 in company stock.

Percentage Held by Insiders

24.40% of the stock of Kronos Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

64.09% of the stock of Kronos Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

KRON Stock Analysis - Frequently Asked Questions

How have KRON shares performed this year?

Kronos Bio's stock was trading at $0.95 at the beginning of the year. Since then, KRON shares have decreased by 6.0% and is now trading at $0.8926.
View the best growth stocks for 2025 here.

How were Kronos Bio's earnings last quarter?

Kronos Bio, Inc. (NASDAQ:KRON) released its quarterly earnings results on Tuesday, March, 18th. The company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.13. The firm had revenue of $2.27 million for the quarter, compared to analyst estimates of $1 million. Kronos Bio had a negative trailing twelve-month return on equity of 64.55% and a negative net margin of 867.66%.

When did Kronos Bio IPO?

Kronos Bio (KRON) raised $175 million in an IPO on Friday, October 9th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler served as the underwriters for the IPO.

Who are Kronos Bio's major shareholders?

Top institutional investors of Kronos Bio include Partners Capital Investment Group LLP (2.38%), Acadian Asset Management LLC (2.02%), Deltec Asset Management LLC (0.25%) and Deuterium Capital Management LLC (0.24%). Insiders that own company stock include Norbert W Bischofberger, Barbara Kosacz, Yasir B Al-Wakeel, Jorge Dimartino, Christopher Dinsmore, Elizabeth A Olek and Deborah Knobelman.
View institutional ownership trends.

How do I buy shares of Kronos Bio?

Shares of KRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kronos Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kronos Bio investors own include Bank of America (BAC), AT&T (T), Taseko Mines (TGB), Energy Transfer (ET), ARMOUR Residential REIT (ARR), Prospect Capital (PSEC) and New Gold (NGD).

Company Calendar

• Last Earnings: 3/18/2025
• Today: 6/13/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KRON
• CIK: 1741830
• Web: kronosbio.com
• Phone: 650-781-5200
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $1.63
• High Stock Price Target: $2.25
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +82.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$112.67 million
• Net Margins: -867.66%
• Pretax Margin: -867.66%
• Return on Equity: -64.55%
• Return on Assets: -48.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.32
• Quick Ratio: 8.32

Sales & Book Value

• Annual Sales: $9.19 million
• Price / Sales: 5.92
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.73 per share
• Price / Book: 0.33

Miscellaneous

• Outstanding Shares: 60,969,000
• Free Float: 45,618,000
• Market Cap: $54.42 million
• Optionable: Optionable
• Beta: 1.63